About Mina Miljevic

Mina is an associate who focuses her practice on life sciences transactions. Mina represents pharmaceutical and biotech companies on complex licensing and collaboration arrangements, manufacturing and supply agreements, and other commercial contracts.

Recent work

• Moderna on a strategic collaboration and license of CytomX's Probody technology for use with Moderna's mRNA therapeutics, including a $35 million upfront cash payment and up to $1.2 billion in milestones.
• AbbVie on a strategic research collaboration and option to license HotSpot Therapeutics’ discovery-stage IRF5 small molecule allosteric therapy for the treatment of autoimmune diseases, including a $40 million upfront cash payment, an additional $295 million in option fees and R&D milestones, and the potential for commercial milestones and royalties.
• Sairopa on its collaboration, option and license agreement with Exelixis to produce novel oncology therapies.
• Sanofi on a long-term research collaboration with Kymera Therapeutics to discover, develop and commercialize first-in-class protein degrader therapies for patients with immune-inflammatory diseases for $150 million upfront and more than $2 billion in potential milestones plus royalties.
• AstraZeneca on its agreement with Samsung Biologics for a $331 million manufacturing agreement to produce bulk drug substance and drug product to support AstraZeneca's biologics therapeutics at Samsung's facility in Incheon, South Korea.
• Novartis on the divestiture of its regional rights to dementia treatment drug Exelon® (rivastigmine patch, capsules and solution) in Canada and Latin America to Knight Therapeutics for $168 million plus an additional milestone payment of up to $12 million upon the achievement of certain conditions.
• A biotechnology company on the acquisition of a solid tumor neoantigen T cell receptor R&D platform and clinical manufacturing facility, which will support the further development of its pipeline of novel cell therapies.
• Celgene Corporation on numerous collaborations including with Evotec AG and Vividion Therapeutics.
• Ferring Pharmaceuticals on its joint investment with Blackstone Life Sciences of up to $570 million in FerGene.
• Morphic Therapeutic on its research and development collaboration with AbbVie for oral integrin therapeutics for fibrosis-related indications.